Posted by Michael Wonder on 22 May 2026
After decade-long climb in Korea, AstraZeneca’s Tagrisso hits access wall
19 May 2026 - AstraZeneca’s Tagrisso has become strong enough in early EGFR mutated lung cancer that Korean doctors say they may have to discuss it after surgery even when patients face the cost without national reimbursement.
The drug, first approved in Korea in 2016 for previously treated EGFR T790M positive non-small cell lung cancer, has moved far beyond late-stage rescue therapy.
